Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:80878 |
Name | IDH-wildtype glioblastoma |
Definition | A glioblastoma that is characterized by high cellularity, high mitotic activity, necrosis or microvascular proliferation and that lacks mutations in IDH genes. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer cell type cancer high grade glioma malignant astrocytoma glioblastoma IDH-wildtype glioblastoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
BRAF V600E | Vemurafenib | IDH-wildtype glioblastoma | predicted - sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | IDH-wildtype glioblastoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03158389 | Phase Ib/II | Vismodegib Alectinib Idasanutlin Temsirolimus Atezolizumab Palbociclib APG101 | NCT Neuro Master Match - N²M² (NOA-20) (N²M²) | Completed | DEU | 0 |
NCT04910022 | Phase Ib/II | NMS-03305293 + Temozolomide Lomustine | Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | Recruiting | USA | ITA | 2 |
NCT04945148 | Phase II | Metformin + Temozolomide | Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide (OPTIMUM) | Not yet recruiting | ITA | FRA | 0 |
NCT05267106 | Phase II | Pemigatinib | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | 3 |
NCT05432375 | Phase I | Tinostamustine | Study of Tinostamustine for Adjuvant Treatment of Glioblastoma | Recruiting | ESP | 1 |
NCT05432518 | Phase I | Olaparib Palbociclib Afatinib Everolimus Dasatinib | GBM Personalized Trial | Recruiting | CAN | 0 |
NCT05463848 | Phase II | Olaparib + Pembrolizumab + Temozolomide Pembrolizumab | Surgical Pembro +/- Olaparib w TMZ for rGBM | Recruiting | USA | 0 |
NCT05465954 | Phase II | NT-I7 + Pembrolizumab | Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT05734560 | Phase Ib/II | 2141 V-11 + D2C7-IT | D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients | Recruiting | USA | 0 |
NCT05765812 | Phase Ib/II | Debio 0123 + Temozolomide | A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma | Recruiting | USA | ESP | 1 |
NCT05879250 | Phase II | WP1066 | WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | Not yet recruiting | USA | 0 |
NCT05917145 | Phase I | WSD-0628 | Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors | Not yet recruiting | USA | 0 |
NCT05986851 | Phase II | Azeliragon | Azeliragon in MGMT Unmethylated Glioblastoma | Recruiting | USA | 0 |
NCT06095375 | Phase I | Regorafenib + Temozolomide | Regorafenib in Combination With Temozolomide With or Without Radiotherapy in Patients With Newly Diagnosed MGMT-Methylated, IDH Wild-type Glioblastoma. (REGOMA-2) | Recruiting | ITA | 0 |
NCT06097975 | Phase I | Ipilimumab + Nivolumab | A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma (NEO-GLITIPNI) | Not yet recruiting | BEL | 0 |